Astrazeneca Ab

Dizal (jiangsu) Pharmaceutical Co., Ltd.

Zeneca Limited

Astra Zeneca U.k. Limited

Astazeneca Ab

Dizal Pharmaceutical Co., Limited

Jason Grant Kettle

Alan Wellington Faull

Sameer Pralhad Kawatkar

Qibin Su

Andrew John Barker

James Francis McCabe

Frederick Woolf Goldberg

Melissa Vasbinder

Claudio Edmundo Chuaqui

James Michael Smith

Neil Patrick Grimster

Robert Hugh Bradbury

Laurent Francois Andre Hennequin

Martin John Packer

Stuart Eric Pearson

Annika Birgitta Margareta Astrand

Magnus K Nilsson

Linette Ruston

Gillian McGregor Lamont

Richard Donald Woessner

Jon James Winter-Holt

Bernard Christophe Barlaam

Sharanjeet Kaur Bagal

Attilla Kuan Tsuei Ting

Anna Ingrid Kristina Berggren

Richard Ducray

Doyle Joseph Cassar

Kurt G Pike

Iain Simpson

Johannes Wilhelmus Maria Nissink

Matti Juhani Lepistö

Matti Juhani Lepisto

Bin Yang

Dedong Wu

Andrew Turner

Wenzhan Yang

Tyler Grebe

Johan R Johansson

Graeme Richard Robb

Tudor Grecu

Karl Magnus Nilsson

Andrew John Eatherton

Scott Boyd

Paul David Kemmitt

Michael Steven Bodnarchuk

Jason Shields

David Buttar

Christopher Phillips

Oliver Ross Steward

James Mccabe

Annika Birgitta Margareta Åstrand

Annika Astrand

Charlene Fallan

Timothy Gordon Rasmusson

Thomas George Christopher Hayhow

Allan W Faull

James Lyman Feron

Scott Gibson Lamont

Shaun Michael Fillery

Anthony Metrano

Annika Birgitta Margareta ÅStrand

Robert Evans Ziegler

Amber Balazs

Ye Wu

Adelphe Mfuh

Li Sha

Kurt Gordon Pike

Linette Lys Ruston

Melissa Marie Vasbinder

Kun Song

Randolph Escobar

Lucas Morrill

Sten Nilsson Lill

Sameer Kawatkar

Kathryn Giblin

The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Fused tricyclic compounds useful as anticancer agents

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R-Rhave any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

JAK1 selective inhibitors

The invention concerns compounds of Formula (I):

Triazolopyrimidine compounds and their use in treating cancer

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Tetracyclic heteroaryl compounds

Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein

Compounds and methods for inhibiting JAK

The invention concerns compounds of Formula (I): 

The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R, R, Rand Rhave any of the meanings hereinbefore defined in the description; process for their preparation, pharmaceutical compositions containing them and their use in treating KIT mediated diseases. 

Phenoxyquinazoline compounds and their use in treating cancer

The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R, R, Rand Rhave any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.

C-anilinoquinazoline compounds and their use in treating cancer

Chemical compounds

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R, R, R, R, R, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

Compounds and their use in treating cancer

C5-anilinoquinazoline compounds and their use in treating cancer

Growing community of inventors

Macclesfield, United Kingdom

Jason Grant Kettle